Figure 2.

Increase in utilization of guideline-recommended therapies in an implementation project: the Atrial Fibrillation registry. Use of guideline-recommended therapies at baseline, 12 months, and 24 months in the longitudinal cohort. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker, CRT, cardiac resynchronization therapy; CRT-P, CRT with pacemaker; CRT-D, CRT with defibrillator; HF, heart failure. *P < 0.001, 12 and 24 months versus baseline. ^†P < 0.001, 12 versus 24 months. ^‡P = 0.007, 12 versus 24 months. ^§P = 0.009, 12 versus 24 months.

Reproduced from Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585–596, http://circ.ahajournals.org/content/122/6/585.²¹